ABSTRACT. Pleiotrophin (PTN) is a heparin-binding growth factor with diverse biological activities, the most studied of these being those related to the nervous system, tumor growth and angiogenesis. Although interest in the involvement of PTN in tumor growth is increasing, many questions remain unanswered, particularly concerning the receptors and the signaling pathways involved. In this review, we briefly introduce PTN, and summarize data on its involvement in tumor growth and angiogenesis, and on what is known to date concerning the receptors and pathways involved.
PTN consists of 168 amino acids, the mature peptide having 136 amino acids as a result of cleavage of the signal peptide [12, 13] . The calculated mass of the mature protein was determined by plasma desorption timeof-flight mass spectrometry as 15,291 kDa, but in SDS-PAGE it appears as 18 kDa [2] , due to the fact that the molecule is rich in cationic amino acids, mainly lysines, that form random coils at both N-and C-terminal ends [12, 14] . The peptide also contains 10 conserved cysteines that participate in the formation of five disulfide bonds [2, 15, 16] , and three potential nuclear targeting sequences K-R/K-X-R /K [2] . PTN does not contain any potential sites for N-glycosylation or other posttranslational modifications [1, 2] and its binding to heparin is mediated by the two central regions that are homologous to the thrombospondin type I repeat (TSR-1) [14] . More recent data suggest that the carboxyl terminal TSR-1 domain is the main heparin-binding site of PTN [17] . The human ptn gene has been identified as being on chromosome 7 band q33a, having a minimum size of 42 kDa, and containing at least seven exons. The open reading frame is located on four exons and the boundaries between introns and extrons seem to be conserved among species in the PTN/MK family [18] . The signal peptide and the first five amino acids of the mature protein are located in exon 2, while the core region is split into exons 2 and 3, containing six and four cysteine residues respectively. Exon 4 comprises the C-terminus of PTN that contains a putative nuclear translocation signal based on its homology with histone Hl [19] . The 5' untranslated region is unique in the human ptn gene compared with other species [20] , while there may be multiple 5' untranslated regions derived from alternative splicing [21] that may contribute to cell or tissue-specific regulation of PTN expression [19] . From what is known to date, the promoter of the human ptn gene contains sequences for the binding of several transcription factors, as shown in figure 1.
REGULATION OF PTN EXPRESSION
Although PTN seems to have significant biological functions, little is still known on the regulation of its expres-sion. It is known that ptn gene expression is regulated in a cell type-and time-dependent manner [5, 13, 19] . It is also known that it is up-regulated during specific diseases, such as rheumatoid arthritis [24] , osteoarthritis [25] , after injury [26, 27] or in cancer (see below). Up-regulation of PTN expression has been mentioned for tumor necrosis factor α and epidermal growth factor [24] , ciliary neurotrophic factor [28] , members of the fibroblast growth factor (FGF) family, such as FGF2 and FGF10 [29, 30] , platelet-derived growth factor [31, 32] , cAMP [33] hypoxia [32] , serum [34] , hydrogen peroxide [35] and endothelial nitric oxide synthase [36] . Contradictory results have been published on retinoic acid, which induces PTN expression in some cells [9, 37] or tissues [30] , but has no effect on other types of cells [31] . Concerning transcription factors, ptn gene expression is directly affected by HOXA5 [38] and AP-1 [35] , after direct binding to the corresponding response elements on the ptn promoter. Finally, loss of the tumor suppressor gene PTEN leads to up-regulation of PTN expression, mediated by the PTEN-PI3K-AKT pathway [39] .
BIOLOGICAL ACTIVITIES OF PTN
The initial reference involving PTN suggested that it plays a role in the maturation and growth of brain [5] . Since then, the importance of PTN in the nervous system has been well described [13, 27, 28, 33, [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] . PTN is over-expressed in neurodegenerative diseases [52] and exhibits a protective or/and trophic effect on dopaminergic neurons in vitro and in vivo [45, 46, 48, 53] . Regarding the muscular system, PTN is expressed in developing muscle in vivo [1, 13, 54] 
Figure 1
Schematic representation of the transcription factor binding sites of the ptn promoter. The human ptn promoter contains a CAAT box, four binding sites for myogenic differentiation 1(MyoD), one for nuclear factors called GT (GT1), two for activator protein 1 (AP1), one for homeobox A5 (HOXA5) and a serum response element (SRE) [19, 29, 32, 33, 36] , all marked with filled squares. Putative binding sites for nuclear factor kappa B (NFκB), cAMP response element binding protein (CBP), serum response factor (CArG box) and retinoic acid receptor (RARE/TRE/VDE) are marked with filled circles [19] and need further investigation. There is also a binding site of Sox10 at the proximal site of the promoter; however, its exact location has not been identified [22] . Potential [101] , and PTN expression is upregulated after loss of the tumor suppressor gene PTEN [39] . Interestingly, it has recently been suggested that decrease of PTN expression in U87MG cells induces tetraploidy and aneuploidy, and arrests cells in the G1 phase of the cell cycle, suggesting that PTN signaling may have a critical role in chromosomal segregation and cell cycle progression [102] . Moreover, PTN disrupts cytoskeletal protein complexes, ablates calcium-dependent homophilic cell-cell adhesion, stimulates ubiquitination and degradation of N-cadherin, reorganizes the actin cytoskeleton and induces a morphological epithelial-mesenchymal transition in PTN-stimulated U373 cells [103] . PTN is also involved in hepatocarcinogenesis and has an antiapoptotic activity against TGFβ1 in hepatoma cell lines [104] . Finally, in line with the notion that PTN may significantly stimulate tumor progression, independently of its effect on the cancer cells themselves, PTN secretion from MCF-7 breast cancer cells stimulates epithelial island formation, activation of stromal fibroblasts, extensive remodeling of the microenvironment and activation of markers of aggressive breast cancer in co-cultures of PTN-expressing MCF-7 and NIH 3T3 cells [105] . It also affects tumor angiogenesis, as discussed more extensively below. Conversely, there are cases where PTN has been shown to negatively regulate tumor cell growth. For example, PTN mRNA levels are decreased in colorectal cancers compared with those in normal adjacent mucosa [106] . It has been detected in lysates and conditioned medium from contact-arrested NIH 3T3 fibroblasts, but not in cells transformed by the ras oncogene [107] , and its expression is up-regulated in confluent compared with actively proliferating cells [108, 109] . Its expression is low or absent in neuroblastomas with a poor prognosis [110] , and negatively affects growth and migration of several glioma cells lines [111, 112] .
Tumor angiogenesis in vitro
Besides a significant role in the biology of tumor cells themselves, PTN seems also to affect the angiogenic potential of tumor cells. Firstly, PTN stimulates angiogenic functions of endothelial cells in vitro [113] [114] [115] [116] [117] and induces embryoid body angiogenesis [118] and transdifferentiation of monocytes into functional endothelial cells [119] [120] [121] . In the same line, it increases the in vitro angiogenic potential of several tumor cells, such as multiple myeloma [120] , breast [122] and prostate [91] cancer cells. In contrast to a positive regulation of in vitro angiogenesis by PTN, there are also data that support a negative regulation. First of all, PTN directly binds and inhibits the effect of vascular endothelial growth factor (VEGF) on endothelial cell proliferation, migration and tube formation [123, 124] . It also decreases the expression of the VEGF receptor KDR, another mechanism through which it potentially inhibits VEGF angiogenic activities in vitro [125] . Finally, decrease in the expression of endogenous PTN in C6 glioma cells significantly increased the angiogenic potential of these cells in vitro, partially due to increased availability and activity of VEGF [111] .
Tumor growth and angiogenesis in vivo
Much in vivo data suggest that PTN plays a role in angiogenesis of tumors that grow in nude mice. This was initially shown in NIH-3T3 cells that constitutively overexpressed PTN. When these cells were implanted into the flanks of nude mice, they tended to form tumors with significant neovascularization compared with the mock-transfected cells [126] . In the same line, overexpression of PTN in a human adrenal carcinoma cell line SW13 promotes not only in vivo tumor growth, but also tumor-induced angiogenesis, suggesting that constitutive PTN signaling fully regulates the angiogenic switch [127] . Expression of PTN in breast cancer MCF-7 cells stimulates tumor growth, remodeling of the microenvironment and tumor-induced angiogenesis in vivo [105, 122] . Ribozyme-mediated depletion of HERV-PTN mRNA in human choriocarcinoma suggests that PTN is an essential and rate-limiting factor for choriocarcinoma growth, invasion, and angiogenesis in vivo [93] . Moreover, RNA interference-mediated gene silencing of PTN suppresses glioblastoma growth and angiogenesis in vivo [128] . Finally, PTN antisense expression in human prostate cancer LNCaP cells inhibits LNCaP cell-induced angiogenesis in vivo in the chicken embryo chorioallantoic membrane [91] . On the other hand, there is also evidence that PTN can act as an angiostatic factor. For example, vascularization was significantly decreased in neuroblastoma xenografts that over-express PTN and that are resistant to the DNAtopoisomerase I inhibitor irinotecan [110] . Similarly, PTN antisense expression in rat glioma C6 cells, increased C6 glioma cell-induced angiogenesis in vivo in the chicken embryo chorioallantoic membrane [111] . In both cases, direct binding of PTN to VEGF has been discussed as the possible reason, although other mechanisms may be also involved.
STRUCTURE-FUNCTION DATA
Many studies have been undertaken in order to determine which regions of PTN are responsible for its diverse functions, in an effort to identify the molecular mechanisms involved and to identify possible therapeutic targets or/and agents. Kilpelainen et al. suggested that the two TSR-1 motifs are responsible for the interaction of PTN with heparin, an interaction associated with many of the biological activities of PTN [14] . More recent data suggest the involvement of only the carboxyl terminal TSR-1 motif in heparin binding [17, 129] , and the mitogenic, transforming and angiogenic activities of PTN in vitro and in vivo in nude mice [129] . It has been shown that PTN exists in two naturally occurring forms, PTN15 and PTN18, with differential interactions with its receptors anaplastic lymphoma kinase (ALK) and receptor protein tyrosine phosphatase β/ζ (RPTPβ/ζ), and different activities. PTN18 interacts with RPTPβ/ζ and induces glioma cell migration, while PTN15 interacts with ALK and induces glioma cell proliferation [97] . The two forms of PTN differ in their carboxyl terminus, which is being investigated for its role in tumor growth and angiogenesis. It has long been shown that the C-terminal lysine-rich domain of PTN (amino acids 111-136) is not involved in neurite outgrowth activity, but it seems to play a key role in the mitogenic and tumor formation activities of PTN [130] . A truncated PTN lacking the C-terminal 111-136 portion inhibits tumor development by inhibition of both endothelial and breast cancer cells [131] . The exact mechanism of action of the C-terminal lysine-rich domain of PTN is not known. It has been suggested that it acts through binding to ALK [132] , or RPTPβ/ζ [133] and antagonizes PTN binding and activity [132, 133] . Since this domain of PTN seems to play an important role in its biological activities related to tumor growth and angiogenesis, more work is needed to identify the molecule(s) with which it interacts, the result(s) of such interactions, as well as its possible therapeutic potential.
RECEPTORS, MOLECULAR MECHANISMS AND INTERACTIONS WITH OTHER MOLECULES INVOLVED IN PTN ACTIONS RELATED TO ANGIOGENESIS AND CANCER

Syndecans
The first identified receptor for PTN has been Nsyndecan [134] . The interaction of PTN with Nsyndecan takes place via its heparan sulfate side chains [134, 135] and is mediated by both TSR-1 domains of PTN [136, 137] . Binding of PTN to N-syndecan promotes several PTN-induced actions in the nervous system [135, [138] [139] [140] . Besides the nervous system, possible involvement of Nsyndecan in PTN activities has been mentioned in osteoblasts [73, 78] , and in parenchymal cells in adult and embryonic liver [61] . No involvement of N-syndecan in PTN-induced activities related to angiogenesis and cancer has been mentioned, nor is it known whether other syndecans interact and mediate PTN-induced actions.
Anaplastic lymphoma kinase (ALK)
ALK is a 220-kDa receptor tyrosine kinase (RTK) encoded by the alk gene on chromosome 2p23. ALK was first identified as part of the NPM-ALK oncogenic fusion protein, resulting from the (2;5)(p23;q35) translocation that is frequently associated with anaplastic largecell lymphoma [141] . Full-length ALK has the typical structure of an RTK, with a large extracellular domain, a lipophilic transmembrane segment, a cytoplasmic tyrosine kinase domain, and belongs to the insulin receptor superfamily. It was initially described as an orphan RTK that shows restricted tissue distribution and is regulated during organ development [142, 143] . PTN was initially identified as a potential ligand of ALK, based on a genetic screen by peptide 'phage display [144] . Different groups have since suggested ALK to be a functional PTN receptor [144] [145] [146] [147] . In support of this, the expression pattern of PTN partially overlaps with that of ALK in the rodent developing nervous system [144] . Beyond ALK expression in the nervous system, cultured fibroblasts and endothelial cells, it has also been detected in osteoblastic cells [148] and chondrocytes [25] , in pancreatic and breast carcinoma [144, 149] , melanoma [150] , neuroblastoma [151] glioblastoma [145, 146] and nonHodgkin's lymphoma [152] . On the other hand, ALK expression is low in a wide variety of soft tumors [153] , and is characterized by limited tissue distribution [142] . Moreover, recent studies performed by different groups argue against PTN as a specific ALK ligand, since binding or activation of ALK by PTN cannot be detected [150, [154] [155] [156] [157] [158] . A possible explanation to the confusion in the literature may be the differential activation of ALK by the two naturally occurring forms of PTN [97] , or the indirect PTNinduced ALK activation through PTN-dependent inactivation of the RPTPβ/ζ [159] .
Receptor protein tyrosine phosphatase β/ζ (RPTPβ/ζ) RPTPβ/ζ was initially isolated from neural tissue as a transmembrane protein-tyrosine-phosphatase (PTPase) that consists of a putative signal peptide, a very large extracellular domain containing an N-terminal sequence homologous to carbonic anhydrase, a transmembrane region and a cytoplasmic portion that contains two repeated PTPase-like domains [160] . A shorter transmembrane and two secreted isoforms corresponding to the extracellular portions of the long and short transmembrane isoforms have been described, all considered splice variants of RPTPβ/ζ [161] [162] [163] . The short transmembrane isoform lacks 859 amino acids from the extracellular domain [161] and also interacts with PTN. Phosphacan, the secreted isoform that corresponds to the extracellular portion of the long RPTPβ/ζ, is also able to bind PTN [162] , and is considered to modulate cell interactions and developmental processes in the nervous system [164] . Changes in chondroitin sulfate on phosphacan are developmentally regulated and regulate phosphacan's affinity for PTN [165] . Phosphacan short isoform that corresponds to the extracellular portion of the short RPTPβ/ζ, is not a proteoglycan [163] and has not been shown to interact with PTN. Apart from the RPTPβ/ζ splicing variants that are normally expressed, under physiological conditions, RPTPβ/ζ is cleaved by matrix metalloproteinase 9, tumor necrosis factor-α converting enzyme, presenilin/γ-secretase [166] and plasmin [167] , leading to secreted, transmembrane, or cytoplasmic forms of, not yet, fully identified biological significance. It has been suggested that PTN binding to RPTPβ/ζ leads to dimerization of the receptor and inhibition of the PTPase activity. The PTN-dependent RPTPβ/ζ inactivation was shown to lead to increased phosphorylation of β-catenin [168] , β-adducin [169] and Fyn [170] , thus regulating cytoskeletal stability, cell plasticity and cellcell adhesion mechanisms [169] . In U373 cells, PTN induced increased tyrosine phosphorylation of different RPTPβ/ζ substrates required for epithelial-mesenchymal transition [103] . On the other hand, PTN binding to RPTPβ/ζ in endothelial cells leads to dephosphorylation and thus activation of c-src, focal adhesion kinase, phosphatidylinositol-3-kinase and mitogen-activated protein kinases, all participating in PTN-induced endothelial cell migration and tube formation on matrigel [116] . We have more recently shown that in order for RPTPβ/ζ to induce cell migration, the presence of α ν β 3 integrin is required. RPTPβ/ζ and α ν β 3 form a functional complex on the surface of endothelial and glioma cell lines, and RPTPβ/ζ seems to be responsible for β 3 tyrosine phosphorylation through the activation of c-src [112] . PTN inhibits migration of cells that do not express α ν β 3 , even if these cells express RPTPβ/ζ [112] , however, the exact mechanism(s) involved are not known.
Other possible (co-)receptors
It has long been shown that PTN interacts with several proteoglycans (PGs) with different affinities [171] , interactions that seem to contribute to PTN dimerization [172] or storage into the extracellular matrix [113] . Among PGs, many reports have implicated a role for chondroitin sulfate (CS) PGs in the PTN-mediated signaling pathway. It has been shown by several studies that PTN interacts especially with over-sulfated CSs [162, 165, [173] [174] [175] , an interaction important for the development of the nervous system [173, 176, 177] and for growth and/or progression of tumors [178] . Versican, a CS-PG with a high content of the E disaccharide units, was found to bind strongly PTN, an interaction abolished by chondroitinase ABC digestion [179] . Similarly, the appican CS chain from rat C6 glioma cells, but not that from SH-SY5Y neuroblastoma cells that contained no E disaccharide, was found to bind specifically PTN [180] . These findings indicate that the E motif is essential for the interaction of the CS chains with PTN. Analysis of the oligosaccharides isolated from embryonic CS/dermatan sulfate (DS) chains revealed that octasaccharide is the minimal size capable of interacting with PTN at a physiological salt concentration, and that PTN binds to multiple sequences in embryonic CS/DS chains with distinct affinity [181] . PTN also binds α ν β 3 , but not α 5 β 1 integrin, an interaction that is responsible for PTN-induced cell migration in both endothelial and glioma cell lines [112] . Integrin α ν β 3 forms a functional complex with RPTPβ/ζ on the cell surface, both components of which are required for the stimulatory effect of PTN on cell migration. Activation of β 3 through phosphorylation of its cytoplasmic tyrosine 773, is required, but is not sufficient to transduce the stimulatory effect of PTN [112] . Further studies are being conducted to elucidate the signaling pathway involved. Interestingly, α ν β 3 is not a receptor for MK [112] , in contrast to all other PTN receptors discussed to date. Finally, PTN binds nucleolin [182] , a 100 kDa multifunctional protein present in the nucleus, cytoplasm, and on the surface of some types of cells, including endothelial [183] and cancer [184, 185] cells. HB-19 pseudopeptide, a specific antagonist that binds the C-terminal tail of nucleolin, has been shown to suppress the growth of tumor cells and angiogenesis in various in vitro and in vivo experimental models [184] . Nucleolin is considered to be a low affinity receptor for PTN, and has been suggested to possibly import PTN into the nucleus [182] . PTN binds nucleolin through its C-TSR-1 domain with a Kd value of 1.3-1.4 x 10-6 M [186] in the absence of heparin. This binding is strongly inhibited by heparin even though it has not been clarified whether the inhibition was caused by the binding of heparin to PTN or nucleolin [182] . Following its binding to cell surface nucleolin, PTN is internalized in a temperature-sensitive manner, which is independent of heparin and CS PGs [186] . What is the role of the interaction of PTN with nucleolin and of the subsequent PTN internalization remains unknown, but is under further investigation for its possible implication in the effects of PTN on tumor growth and angiogenesis.
CONCLUSION
Although many aspects remain obscure, PTN seems to be significant for tumor growth and angiogenesis, possibly through diverse mechanisms. Clarification of the receptors, as well as the signaling pathways involved, is of great importance, both for increasing our knowledge concerning cancer growth, and for developing new therapeutic strategies. 
